Granted Patent
B2
US 12,448,448 · App. 16/444,691 · Granted Oct 21, 2025
Anti-PD-1 antibodies and uses thereof
Inventors:
Mark Cornfeld (Philadelphia, PA); Naimish Bharat Pandya (Rockville, MD); Jon Marc Wigginton (Rockville, MD); Ross La Motte-Mohs (Rockville, MD); Bradley James Sumrow (Rockville, MD)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods of treatment of cancer with antibodies and antibody fragments that bind to PD-1 are disclosed.
Claims (7)
1. A method of treating Merkel cell carcinoma in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an antibody that binds to human PD-1, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3,
and wherein the antibody is administered at a dose of 500 mg once every four weeks.
2. The method of claim 1 , wherein the antibody is administered intravenously.
3. The method of claim 1 , wherein the antibody is administered via continuous infusion.
4. The method of claim 1 , wherein the antibody is administered to the subject in a composition that comprises about 1 mg/mL to 100 mg/ml or about 10 mg/mL to 100 mg/ml or about 50 to 250 mg/mL or about 100 to 150 mg/ml or about 100 to 250 mg/ml of anti-PD-1 antibody.
5. The method of claim 1 , wherein the antibody is produced in mammalian cells.
6. The method of claim 5 , wherein the antibody is produced in Chinese Hamster Ovary (CHO) cells.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 15, 2020
From: CORNFELD, MARK
To: INCYTE CORPORATION
Reel/Frame 052407/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 15, 2020
From: PANDYA, NAIMISH BHARAT; WIGGINTON, JON MARC; MOTTE-MOHS, ROSS LA; SUMROW, BRADLEY JAMES
To: MACROGENICS, INC.
Reel/Frame 052407/0844 →
Continuity (3)
Provisional Application
62756319
· Nov 6, 2018
Provisional Application
62687673
· Jun 20, 2018
References Cited (224)
US 4399216A
· Axel et al.
· 1983
[cited by applicant]
US 4634665A
· Axel et al.
· 1987
[cited by applicant]
US 5057313A
· Shih et al.
· 1991
[cited by applicant]
US 5156840A
· Goers et al.
· 1992
[cited by applicant]
US 5179017A
· Axel et al.
· 1993
[cited by applicant]
US 5530101A
· Queen et al.
· 1996
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5693761A
· Queen et al.
· 1997
[cited by applicant]
US 5693762A
· Queen et al.
· 1997
[cited by applicant]
US 5714350A
· Co et al.
· 1998
[cited by applicant]
US 5731168A
· Carter et al.
· 1998
[cited by applicant]
US 5849992A
· Meade et al.
· 1998
[cited by applicant]
US 5859205A
· Adair et al.
· 1999
[cited by applicant]
US 5869046A
· Presta et al.
· 1999
[cited by applicant]
US 6300064B1
· Knappik et al.
· 2001
[cited by applicant]
US 6350861B1
· Co et al.
· 2002
[cited by applicant]
US 6407213B1
· Carter et al.
· 2002
[cited by applicant]
US 6803192B1
· Chen
· 2004
[cited by applicant]
US 6808710B1
· Wood et al.
· 2004
[cited by applicant]
US 7029674B2
· Carreno et al.
· 2006
[cited by applicant]
US 7101550B2
· Wood et al.
· 2006
[cited by applicant]
US 7488802B2
· Collins et al.
· 2009
[cited by applicant]
US 7563869B2
· Honjo et al.
· 2009
[cited by applicant]
US 7595048B2
· Honjo et al.
· 2009
[cited by applicant]
US 7635757B2
· Freeman et al.
· 2009
[cited by applicant]
US 7722868B2
· Freeman et al.
· 2010
[cited by applicant]
US 7794710B2
· Chen et al.
· 2010
[cited by applicant]
US 7851598B2
· Davis
· 2010
[cited by applicant]
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8168757B2
· Finnefrock et al.
· 2012
[cited by applicant]
US 8287856B2
· Li et al.
· 2012
[cited by applicant]
US 8354509B2
· Carven et al.
· 2013
[cited by applicant]
US 8460886B2
· Shibayama et al.
· 2013
[cited by applicant]
US 8709416B2
· Langermann et al.
· 2014
[cited by applicant]
US 8735553B1
· Li et al.
· 2014
[cited by applicant]
US 8927697B2
· Davis et al.
· 2015
[cited by applicant]
US 8993731B2
· Tyson
· 2015
[cited by applicant]
US 9102727B2
· Freeman et al.
· 2015
[cited by applicant]
US 9102728B2
· Tyson
· 2015
[cited by applicant]
US 9132281B2
· Zeng et al.
· 2015
[cited by applicant]
US 9205148B2
· Langermann et al.
· 2015
[cited by applicant]
US 9217034B2
· Li et al.
· 2015
[cited by applicant]
US 9220776B2
· Sharma et al.
· 2015
[cited by applicant]
US 9243052B2
· Olive et al.
· 2016
[cited by applicant]
US 9534052B2
· Eisenbach-Schwartz et al.
· 2017
[cited by applicant]
US 9598491B2
· Ahmed et al.
· 2017
[cited by applicant]
US 9637546B2
· Olive et al.
· 2017
[cited by applicant]
US 9676853B2
· Zhou et al.
· 2017
[cited by applicant]
US 9683048B2
· Freeman et al.
· 2017
[cited by applicant]
US 9701749B2
· Shibayama et al.
· 2017
[cited by applicant]
US 20050008625A1
· Balint et al.
· 2005
[cited by applicant]
US 20050059051A1
· Chen
· 2005
[cited by applicant]
US 20050079574A1
· Bond
· 2005
[cited by applicant]
US 20080311117A1
· Collins et al.
· 2008
[cited by applicant]
US 20120251537A1
· Ahmed et al.
· 2012
[cited by applicant]
US 20120269806A1
· Sykes
· 2012
[cited by applicant]
US 20140234331A1
· Korman et al.
· 2014
[cited by applicant]
US 20150344577A1
· Fu
· 2015
[cited by applicant]
US 20160158360A1
· Hernandez
· 2016
[cited by examiner]
US 20160347836A1
· Grosso
· 2016
[cited by applicant]
US 20170165325A1
· Sharpe et al.
· 2017
[cited by applicant]
US 20170226182A1
· Chomont et al.
· 2017
[cited by applicant]
US 20220233529A1
· Wang et al.
· 2022
[cited by applicant]
CN 105960415
· 2016
[cited by applicant]
EP 0404097
· 1990
[cited by applicant]
WO WO9007861
· 1990
[cited by applicant]
WO WO9311161
· 1993
[cited by applicant]
WO WO0114557
· 2001
[cited by applicant]
WO WO0139722
· 2001
[cited by applicant]
WO WO02086083
· 2002
[cited by applicant]
WO WO2005003175
· 2005
[cited by applicant]
WO WO2005018572
· 2005
[cited by applicant]
WO WO2013181452
· 2013
[cited by applicant]
WO WO2014074852
· 2014
[cited by applicant]
WO WO2014179664
· 2014
[cited by applicant]
WO WO2015058573
· 2015
[cited by applicant]
WO WO2015195163
· 2015
[cited by applicant]
WO WO2016014688
· 2016
[cited by applicant]
WO WO2016020856
· 2016
[cited by applicant]
WO WO2016057933
· 2016
[cited by applicant]
WO WO2016068801
· 2016
[cited by applicant]
WO WO2016077397
· 2016
[cited by applicant]
WO WO2016191751
· 2016
[cited by applicant]
WO WO2016197497
· 2016
[cited by applicant]
WO WO2016201051
· 2016
[cited by applicant]
WO WO2017016497
· 2017
[cited by applicant]
WO WO2017019846
· 2017
[cited by applicant]
WO WO2017019896
· 2017
[cited by applicant]
WO WO2017024515
· 2017
[cited by applicant]
WO WO2017025051
· 2017
[cited by applicant]
WO WO2017019846A1
· 2017
[cited by examiner]
WO WO2017054646
· 2017
[cited by applicant]
WO WO2017055443
· 2017
[cited by applicant]
WO WO2017055547
· 2017
[cited by applicant]
WO WO2017058115
· 2017
[cited by applicant]
WO WO2017062619
· 2017
[cited by applicant]
WO WO2017071625
· 2017
[cited by applicant]
WO WO2017087599
· 2017
[cited by applicant]
WO WO2017096026
· 2017
[cited by applicant]
WO WO2017106061
· 2017
[cited by applicant]
WO WO2017106656
· 2017
[cited by applicant]
WO WO2017107885
· 2017
[cited by applicant]
WO WO2017124050
· 2017
[cited by applicant]
MacroGenics_2016_RnD_Day_-_FINAL_website_download_.pdf, accessed May 17, 2021 from http:/web.archive.org/web/20210517161118/http://ir.macrogenics.com/static-files/a35326eb-2be4-4859-837e-bb0b4f3a7da0 (Year: 2016).
[cited by examiner]
Medlineplus, MSH6 Gene, https://medlineplus.gov/genetics/gene/msh6/, accessed May 19, 2021 (Year: 2020).
[cited by examiner]
Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017;28(5):1036-1041. (Year: 2017).
[cited by examiner]
Chan IS et al. Journal for Immuno Therapy of Cancer (2018) 6:23 1-6 (Year: 2018).
[cited by examiner]
Doherty K et al. Retifanlimab Adds FDA-Approved Option to Merkel Cell Carcinoma Treatment Landscape. (OncLive Mar. 14, 2025 https://www.onclive.com/view/retifanlimab-adds-fda-approved-option-to-merkel-cell-carcinoma-tre…
[cited by examiner]
Fojnica A et al. An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy. (Cancers 2023, 15(20), 5084) (Year: 2023).
[cited by examiner]
International Preliminary Report on Patentability in International Application No. PCT/US2019/037750, dated Dec. 22, 2020, 13 pages.
[cited by applicant]
Agata et al., “Expression Of The PD-I Antigen On The Surface Of Stimulated Mouse T And B Lymphocytes,” Int Immunol., 1996, 8(5):765-772.
[cited by applicant]
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol Immunol., 1993, 30(1):105-108.
[cited by applicant]
Berge, et al. “Pharmaceutical Salts,” J Pharm Sci., 1977, 66:1-19.
[cited by applicant]
Better et al., “
[cited by applicant]
Better et al., “Expression of engineered antibodies and antibody fragments in microorganisms,” Methods in Enzymology, 1989, 178:476-496.
[cited by applicant]
Bird et al., “Single chain antibody variable regions,” TIBTECH, 1991, 9:132-137.
[cited by applicant]
Blank et al., “Contribution Of The PD-L1/PD-1 Pathway To T-Cell Exhaustion: An Update On Implications For Chronic Infections And Tumor Evasion Cancer,” Immunol Immunother., 2006, 56(5):739-745.
[cited by applicant]
Boyd, “Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen,” Drug Development Research, Feb. 1995, 34(2):91-109.
[cited by applicant]
Carter et al., “High level
[cited by applicant]
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” PNAS., May 15, 1992, 89(10):4285-4289.
[cited by applicant]
Chothia et al., “Structural repertoire of the human VH segments,” J Mal Bio., 1992, 227:799-817.
[cited by applicant]
Co et al., “A humanized antibody specific for the platelet integrin gpIIb/IIIa,” J Immunol., Mar. 15, 1994, 152(6):2968-2976 (Abstract Only).
[cited by applicant]
Cook et al., “The human immunoglobulin VH repertoire,” Immunol Today., 1995, 16(5):237-242.
[cited by applicant]
Davies et al., “Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability,” Protein Eng., 1996, 9(6):531-537.
[cited by applicant]
Dizon et al., “Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation,” The Oncol., Feb. 22, 2018, 23(6):650-653.
[cited by applicant]
Dorai et al., “Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function,” Hybridoma, Apr. 1991, 10(2):211-217.
[cited by applicant]
Flies et al., “The New B7s: Playing a Pivotal Role in Tumor Immunity” J Immunother., Apr. 2007, 30(3):251-260.
[cited by applicant]
Friend, “Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection,” Transplantation, Dec. 15, 1999, 68(11):1632-1637.
[cited by applicant]
Genbank Accession No. NP_005009, Mar. 29, 2020, 5 pages.
[cited by applicant]
Gennaro, “Remington: The Science and Practice of Pharmacy,” Lippincott, Williams & Wilkins, 2000, 20th ed., 1053 pages.
[cited by applicant]
Graddis et al., “Designing Proteins That Work Using Recombinant Technologies ,” Curr Pharm Biotechnol., 2002 3(4):285-297.
[cited by applicant]
Hand et al., “Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant,” Cancer Immunol Immunother., 1992, 35(3):165-174.
[cited by applicant]
Harmsen et al., “Properties, production, and applications of camelid single-domain antibody fragments,” Appl Microbial Biotechnol., Aug. 18, 2007, 77(1):13-22.
[cited by applicant]
Hobbs et al., “Interaction of aglycosyl immunoglobulins with the IgG Fc transport receptor from neonatal rat gut: Comparison of deglycosylation by tunicamycin treatment and genetic engineering,” Mol Immunol., 1992, 29(7…
[cited by applicant]
Holliger et al., “‘Diabodies’: small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci USA., 1993, 90(14):6444-6448.
[cited by applicant]
Hudson, et al., “High avidity scFv multimers; diabodies and triabodies,” J Immunol Methods., Dec. 10, 1999, 231(1-2):177-189.
[cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
International Invitation to Pay Fees in International Application No. PCT/US2019/037750, dated Oct. 10, 2019, 19 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2019/037750, dated Dec. 4, 2019, 22 pages.
[cited by applicant]
Isaacs, “Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.,” J Immunol., May 15, 1992, 148(10):3062-3071.
[cited by applicant]
Ishida et al., “Induced Expression Of Pd-I, A Novel Member Of The Immunoglobulin Gene Superfamily, Upon Programmed Cell Death,” EMBO J., 1992, 11(11):3887-3895.
[cited by applicant]
Kaufman and Sharp “Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary dna gene.,” Mol Biol., Aug. 1982, 159(4):601-621.
[cited by applicant]
Lamoyi, E., “Preparation of F(ab')2 fragments from mouse IgG of various subclasses,” Methods in Enzymology, 1986 121:652-663.
[cited by applicant]
Leatherbarrow and Dwek, “The effect of aglycosylation on the binding of mouse IgG to staphylococcal protein A,” Febs Letters, Dec. 12, 1983, 164(2):227-230.
[cited by applicant]
Leatherbarrow et al., “Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor.,” Mol Immunol., 1985, 22(4):407-415.
[cited by applicant]
Lei et al., “Characterization of the Erwinia carotovora pelB gene and its product pectate lyase,” J Bacterial., Sep. 1987, 169:4379-4383.
[cited by applicant]
Makker et al., “New therapies for advanced, recurrent, and metastatic endometrial cancers,” Gynecol Oncol Res Pract., Dec. 2, 2017, 4:19.
[cited by applicant]
Martin-Orozco et al., “Inhibitory Costimulation And Anti Tumor Immunity” Semin. Cancer Biol., 2007, 17(4):288-298.
[cited by applicant]
Mehnert et al., “Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer,” J Clin Invest., Jun. 1, 2016, 126(6):2334-2340.
[cited by applicant]
Milstein et al., “Hybrid hybridomas and their use in immunohistochemistry,” Nature, Oct. 6, 1983, 305:537-540.
[cited by applicant]
Mizushima et al., “pEF-BOS, a powerful mammalian expression vector,” Nucleic Acids Res., Sep. 11, 1990, 18:5322.
[cited by applicant]
Moller et al., “Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain,” J Biol. Chem., Dec. 3, 2010, 285(49):38348-38361.
[cited by applicant]
Morrison, “Transfectomas provide novel chimeric antibodies,” Science, Sep. 20, 1985, 229(4719):1202-1207.
[cited by applicant]
Mulligan et al., “Synthesis of rabbit beta-globin in cultured monkey kidney cells following infection with a SV40 beta-globin recombinant genome,” Nature, Jan. 11, 1979, 277(5692):108-114.
[cited by applicant]
Nishimura et al., “Facilitation Of Beta Selection And Modification Of Positive Selection In The Thymus Of PD-I-Deficient Mice” J Exp Med., Mar. 6, 2000, 191(5):891-898.
[cited by applicant]
Nose and Wigzell, “Biological significance of carbohydrate chains on monoclonal antibodies,” Proc Natl Acad Sci USA., Nov. 1983, 80(21):6632-6636.
[cited by applicant]
Ott et al., “Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study,” J Clin Oncol., Aug. 1, 2017, 35(22):2535-2541.
[cited by applicant]
Powers et al., “Expression of single-chain Fv-Fc fusions in Pichia pastoris,” J Immunol Methods, May 1, 2001, 251(1-2):123-135.
[cited by applicant]
Raju, “Glycosylation variations with expression systems,” BioProcess International, Apr. 2003, pp. 44-53.
[cited by applicant]
Rousseaux et al., “Optimal conditions for the preparation of proteolytic fragments from monoclonal IgG of different rat IgG subclasses,” Methods in Enzymology, 1986, 121:663-669.
[cited by applicant]
Santin et al., “Regression of Chemotherapy-Resistant Polymerase & (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab,” Clin Canc Res., Dec. 1, 2016, 22(23):5682-5687.
[cited by applicant]
Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem. 2001, …
[cited by applicant]
Shields et al., “Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity,”
[cited by applicant]
Shinkawa et al., “The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cyt…
[cited by applicant]
Tao et al., “Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region,” J Immunol., Oct. 15, 1989, 143(8):2595-2601 (Abstr…
[cited by applicant]
Tempest et al., “Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo,” Biotechnology, Mar. 1991, 9(3):266-271.
[cited by applicant]
Tomlinson et al., “The repertoire of human germline vH sequences reveals about fifty groups of VH segments with different hypervariable loops,” J Mal Biol., Oct. 5, 1992, 227:776-798.
[cited by applicant]
Tomlinson et al., “The structural repertoire of the human V kappa domain,” EMBO J, Sep. 15, 1995, 14(18):4628-4638.
[cited by applicant]
Tomlinson et al., “V Base: The database fof human antibody genes,” MRC Centre for Protein Engineering, Cambridge, UK, 1997 [retrieved on Oct. 30, 2020], retrieved from URL <https://www2.mrc-lmb.cam.ac.uk/vbase/vbase-int…
[cited by applicant]
Umana et al., “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity,” Nat Biotechnol., Feb. 1999, 17(2):176-180.
[cited by applicant]
Urlaub and Chasin “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” Proc Natl Acad Sci., Jul. 1, 1980, 77(7):4216-4220.
[cited by applicant]
Ward and Ghetie, “The effector functions of immunoglobulins: implications for therapy,” Therapeutic Immunology, Apr. 1995, 2(2):77-94 (Abstract Only).
[cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Wright & Morrison, “Effect of glycosylation on antibody function: implications for genetic engineering,” Trends in Biotech., Jan. 1997, 15(1):26-32.
[cited by applicant]
Yamazaki et al., “Expression Of Programmed Death I Ligands By Murine T-Cells And APC” J Immunol., Nov. 15, 2002, 169(10):5538-5545.
[cited by applicant]
Gibney et al., “Abstract P313: INCMGA 0012-201: A Phase 2 Study of INCMGA00012 in Patients with Metastatic Merkel Cell Carcinoma,” Poster, Presented at 33rd Annual Meeting of the Society for Immunotherapy of Cancer, Nov…
[cited by applicant]
Lakhani et al., “Abstract P249: A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics (PK) of MGA012 (anti-PD-1 antibody) in Patients with Advanced Solid Tumors,” Poster, Presented Society for Immunotherapy …
[cited by applicant]
Mehnert et al., “Abstract 669: First-in-Human Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors: Interim Results of the Cohort Expansion Phase,” Poster, Presented at the 33rd Annual Meeting of the Soci…
[cited by applicant]
Rao et al., “Abstract P336: An International, Single-Arm, Phase 2 Study of INCMGA00012 in Patients with Advanced Squamous Carcinoma of the Anal Canal (SCAC) Who Have Progressed Following Platinum-Based Chemotherapy (NCT…
[cited by applicant]
Nghiem et al., “PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma,” N Engl J Med., Jun. 30, 2016, 374(26):2542-2552.
[cited by applicant]
Extended European Search Report in European Application No. 24151431.4, dated May 23, 2024, 12 pages.
[cited by applicant]
Morris et al., “Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study,” The Lancet Oncology, Apr. 2017, 18(4):446-453.
[cited by applicant]
Sclafani et al., “Systemic therapies for advanced squamous cell anal cancer,” Current oncology reports, Jul. 2018, 20(53):1-11.
[cited by applicant]
Topalian et al., “Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell c…
[cited by applicant]
Walocko et al., “Metastatic Merkel cell carcinoma response to nivolumab,” Journal for ImmunoTherapy of Cancer, Dec. 2016, 4(79):1-4.
[cited by applicant]
Winkler et al., “PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma,” British Journal of Dermatology, Jan. 2017, 176(1):216-219.
[cited by applicant]
Barroso-Sousa et al., “PD-1 inhibitors in endometrial cancer,” Oncotarget, Nov. 21, 2017, 8(63):106169-106170.
[cited by applicant]
Bai et al., “A guide to rational dosing of monoclonal antibodies,” Clinical Pharmacokinetics, Feb. 1, 2012, 51(2):119-135.
[cited by applicant]
Chen et al., “Abstract LB-268: Assessment of flat dosing strategy for INCMGA00012 in patients with advanced tumors,” Poster, Presented at Proceedings of the American Association for Cancer Research Annual Meeting 2019, …
[cited by applicant]
Committee for Medicinal Products for Human Use (CHMP), “Withdrawal assessment report: Zynyz, International non-proprietary name: retifanlimab,” Procedure No. EMEA/H/C/005632/0000, European Medicines Agency, Jun. 24, 202…
[cited by applicant]
Freshwater et al., “Evaluation of dosing strategy for pembrolizumab for oncology indications,” Journal for ImmunoTherapy of Cancer, May 16, 2017, 5:43, 16 pages.
[cited by applicant]
Rao et al., “A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202),” ESMO Open, Aug. 2022, 7(4):10052…
[cited by applicant]
Wang et al., “Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials,” Journal of Clinical Pharmacology, Sep. 2009, 49(9): 1012-1024.
[cited by applicant]
Zhang et al., “Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults,” Journal of Clinical Pharmacology, Jan. 2012, 52(1):18-28.
[cited by applicant]
Zhao et al., “Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors,” Annals of Oncology, Aug. 1, 2017, 28:2002-2008.
[cited by applicant]